Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Background. Type 2 diabetes is common, largely managed in primary care and requires effective glycaemic control to reduce the risk of microvascular complications. Oral hypoglycaemic agents are typically the first pharmacological intervention used to improve glycaemic control. Objectives. To evaluate the management of people with type 2 diabetes with oral hypoglycaemic agents in primary care. Methods. This retrospective cohort study included people with type 2 diabetes treated with oral agents drawn from 243 general practices in the UK over a 5-year study period from 1999 to 2003. Primary outcome measures were glycaemic monitoring and control on oral hypoglycaemic agents. Results. Of the 71 561 patients identified with prevalent type 2 diabetes, 20 922 received their first prescription for an oral hypoglycaemic agent during the study. Only 49% of patients had a recorded HbA 1c within 6 months of starting therapy. Forty per cent of patients had poor glycaemic control (HbA 1c ≥ 7.5%) after starting a single hypoglycaemic agent. There was a statistically significant association between post-therapy HbA 1c with pre-therapy HbA 1c , metformin dose, age and geodemographical classification. Greater reductions in HbA 1c were observed in older patients, those with a high pre-treatment HbA 1c and those from less-deprived areas. Patients remained on a single therapy for a median of 3.8 years. During the study, 7009 of those who started a single agent were prescribed a second agent. Of those with a recorded HbA 1c , 50% had poor glycaemic control (HbA 1c ≥ 7.5%) post-therapy. Conclusions. Management of type 2 diabetes with oral hypoglycaemic agents appears to be suboptimal for many patients. Oral treatment is often not started until glycaemic control is poor, and many patients do not receive adequate monitoring or have poor glycaemic control following treatment with oral agents. Many patients with a high pre-treatment HbA 1c are not controlled on a single oral agent even at high dose suggesting that earlier, more aggressive treatment in primary care is required. © The Author 2007. Published by Oxford University Press. All rights reserved.

Original publication

DOI

10.1093/fampra/cmm008

Type

Journal article

Journal

Family Practice

Publication Date

01/06/2007

Volume

24

Pages

224 - 229